C6ACBA34-164B-419D-9C2B-ED2DC3C68FDD
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 20.66360052562418
- age_years
- 52
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.494
- INTERFERON_ALPHA_RESPONSE+0.481
- HEDGEHOG_SIGNALING+0.429
- WNT_BETA_CATENIN_SIGNALING+0.416
- NOTCH_SIGNALING+0.397
- TGF_BETA_SIGNALING+0.385
- MYC_TARGETS_V2+0.362
- PROTEIN_SECRETION+0.328
- MITOTIC_SPINDLE+0.308
- INTERFERON_GAMMA_RESPONSE+0.299
Top 10 suppressed
- KRAS_SIGNALING_DN-0.297
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
- SPERMATOGENESIS-0.285
- ALLOGRAFT_REJECTION-0.170
- MYOGENESIS-0.167
- COAGULATION-0.160
- ANGIOGENESIS-0.120
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.099
- ESTROGEN_RESPONSE_LATE-0.025
- E2F_TARGETS-0.021
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 6114E89B-B007-4F1B-B086-21ADE26F4573 | — | — | 0.910 |
| 2 | C81B24AB-2DBA-4624-A1D4-D4DCAC714506 | — | — | 0.890 |
| 3 | SRR934756 | — | — | 0.879 |
| 4 | 8441B707-EC45-4A38-8B83-99B8D83CCF8B | — | — | 0.873 |
| 5 | 7CE18C10-61E6-45FA-B9AF-408CD673C0C9 | — | — | 0.856 |
| 6 | 67B5E93E-6F06-4247-86DD-A914279EFFC5 | — | — | 0.854 |
| 7 | A1203AFB-95EC-4EAF-9290-BDB74432403C | — | — | 0.842 |
| 8 | 7E9D6B6D-3276-4240-B5C5-F3F982076358 | — | — | 0.836 |
| 9 | SRR934764 | — | — | 0.834 |
| 10 | 76987B28-B56B-4A1F-B77C-1E08B8EFEF90 | — | — | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.494 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.481 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.429 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.416 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.397 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.385 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.362 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.328 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.308 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.299 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.264 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.263 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.235 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.224 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.194 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.192 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.177 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.166 | Inavolisib | — uncovered |